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Abstract
Background: Human papillomavirus (HPV) infection has been shown to be a major risk factor for cervical cancer.
Vaccines against HPV-16 and HPV-18 are highly effective in preventing type-specific HPV infections and related
cervical lesions. There is, however, limited data available describing the health and economic impacts of HPV
vaccination in Taiwan. The objective of this study was to assess the cost-effectiveness of prophylactic HPV
vaccination for the prevention of cervical cancer in Taiwan.
Methods: We developed a Markov model to compare the health and economic outcomes of vaccinating
preadolescent girls (at the age of 12 years) for the prevention of cervical cancer with current practice, including
cervical cytological screening. Data were synthesized from published papers or reports, and whenever possible,
those specific to Taiwan were used. Sensitivity analyses were performed to account for important uncertainties and
different vaccination scenarios.
Results: Under the assumption that the HPV vaccine could provide lifelong protection, the massive vaccination
among preadolescent girls in Taiwan would lead to reduction in 73.3% of the total incident cervical cancer cases
and would result in a life expectancy gain of 4.9 days or 8.7 quality-adjusted life days at a cost of US$324 as
compared to the current practice. The incremental cost-effectiveness ratio (ICER) was US$23,939 per life year
gained or US$13,674 per quality-adjusted life year (QALY) gained given the discount rate of 3%. Sensitivity analyses
showed that this ICER would remain below US$30,000 per QALY under most conditions, even when vaccine
efficacy was suboptimal or when vaccine-induced immunity required booster shots every 13 years.
Conclusions: Although gains in life expectancy may be modest at the individual level, the results indicate that
prophylactic HPV vaccination of preadolescent girls in Taiwan would result in substantial population benefits with a
favorable cost-effectiveness ratio. Nevertheless, we should not overlook the urgency to improve the compliance
rate of cervical screening, particularly for older individuals.
Background
Cervical cancer is one of the most common female
malignancies worldwide. The cervical cancer rate has
declined in Taiwan over the last decade, an effect largely
attributed to widespread screening for cervical cancer.
Nonetheless, the compliance with cervical screening in
Taiwan remains suboptimal that the annual screening
rate was 28.6% for women aged over 30 years [1], and
the incidence of cervical cancer is consistently higher
than those in neighboring countries [2]. In 2006, there
was an annual incidence rate of 16.2 per 100,000 people
for invasive cervical cancer and a mortality rate of 7.8
per 100,000 people in comparison with breast cancer
incidence and mortality of 61.1 and 12.8 per 100,000
people, respectively [3].
Genital infection with human papillomavirus (HPV)
has been well established to be the determining cause of
cervical cancer [4,5]. Researchers reported the HPV pre-
valence in Taiwan was around 10-20% [6-9]. While HPV
comprises a wide range of genotypes, several types are
defined as high-risk, or oncogenic, for their strong carci-
nogenicity. A primary preventive measure involving
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has thus been developed, and there are two vaccines
that are currently available. One is the bivalent vaccine
[10,11], and the other is the quadrivalent vaccine [12],
which commonly target the HPV-16 and HPV-18. Safety
and satisfactory efficacy against type-specific HPV infec-
tion and related precancerous lesions have been demon-
strated for both vaccines. Although their efficacy for
preventing cervical cancer has not been comprehensively
proven yet, it seems reasonable to expect such an
outcome.
A number of studies have been conducted to evaluate
the potential cost-effectiveness for prevention of cervical
cancer through HPV vaccination, with a range of results
[13-26]. Indeed, the cost-effectiveness of HPV vaccina-
tion varies between regions by many factors including
different epidemiology of HPV infection and cervical
screening efforts; Puig-Junoy and Lopez-Valcarcel
reported that large variations existed in the cost-effective-
ness results of different studies even for the same country
[27]. Currently, there are still limited data evaluating the
economic impact of cervical cancer vaccination in Tai-
wan [28,29]. The aim of this study was therefore to assess
the cost-effectiveness of prophylactic HPV vaccination
on the prevention of cervical cancer in Taiwan.
Methods
Decision model
We developed a Markov model [30] to assess the cost-
effectiveness of the prophylactic vaccine against high-
risk HPV infections and related cervical cancers in Tai-
wan (Figure 1) using the TreeAge software (TreeAge
Software, Inc., Williamstown, MA, USA). The perspec-
tive of analysis considered in this study was that of the
healthcare payers. The target population for our analysis
included all adolescent girls in Taiwan; the time horizon
was lifetime.
Our model simulated the natural history of a hypothe-
tical cohort of 12-year-old girls who were either admi-
nistered the cervical cancer vaccine or who received the
current standard of care from adolescence to death. For
each strategy, the model incorporated probabilities of
occurrence and progression of high-risk HPV, of squa-
mous intraepithelial lesions (SIL) and of cervical cancer,
as well as the probability of death, quality of life and
costs associated with the corresponding health states.
Every year, each person is at risk of developing high-risk
HPV, SIL or cervical cancer. Over time, an infected
woman’s HPV infection can regress, persist or progress
into SIL. High-grade SIL may possibly progress to cervi-
cal cancer. In addition to being at risk for death caused
by cervical cancer, all women are still at risk for age-
specific death that is unrelated to cervical cancer.
We assumed that girls with and without vaccination
would receive the same standard of care that is currently
being implemented, which includes routine papanico-
laou (Pap) tests for compliant women every year starting
from 30 years of age. At each screening event, cervical
lesions are detected based on the sensitivity of the
screening test [31,32]. Follow-up and/or treatment will
take place depending on the type of detected lesion with
a certain probability of success.
Model parameters and base case assumptions
Transition probabilities for the hypothetical cohort from
one clinical state to another over time were derived
from published papers, reports or expert opinions.
Whenever possible, data specific to Taiwan were used.
Detailed information is provided in Table 1 which
depicts the base case value, range for sensitivity analysis
and data source for input parameters. The base case
value represents our best estimate for each variable.
HPV infection
The natural history of HPV infection is complex, and
clearance or persistence of infection, together with pro-
gression to SIL, differ depending on the genotype of
HPV, patient characteristics and study design. To sim-
plify the procedure, we only classified the HPV geno-
types into high- and low-risk. Our age-specific estimates
for incidence, progression and regression were averages
for all types of oncogenic HPV (such as HPV-16, 18, 31,
33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 68 and 70) based
o nt h ep o p u l a t i o np r e v a l e n c ed a t a[ 6 - 9 ] .I no u rb a s e
case analysis, the annual incidence infection began at
age 15, peaked at age 20 and dropped off after age 35.
Given HPV infection, regression rates were highest for
women < 25 years (46%/yr) and lowest for women > 50
years (3%/yr), reflecting an observation of more persis-
tent infections in the older age group [33-38].
Cervical cancer
In the model calibration process, the transition probabil-
ities for progression from high-risk HPV infection to
low-grade SIL, from low-grade to high-grade SIL and
from high-grade SIL to cervical cancer varied within
valid ranges derived from published papers to fit the
model-predicted incidence rates of cervical cancer with
data taken from the National Cancer Registry of Taiwan
The probability of diagnosing asymptomatic cervical
lesions is a function of a woman’s likelihood of receiving
a cervical screening and on the sensitivity and specificity
of this test [31,32]. The Taiwanese government launched
a nationwide cervical screening program in July of 1995,
in which annual Pap smear screenings were offered to
women aged over 30 years. According to current reports
in Taiwan, the annual compliance rate for Pap testing is
approximately 30% by age 60, which proportionately
declines to 15% at age 70 or older [1,39].
Liu et al. BMC Health Services Research 2010, 10:11
http://www.biomedcentral.com/1472-6963/10/11
Page 2 of 11The National Cancer Registry of Taiwan provided us
with the average survival function of invasive cervical
cancer, which does not differentiate at different clinical
stages. From 1990 to 2005, the registry collected a total
of 39,470 cases, which were linked with our National
Mortality Registry between 1990 and 2007 to determine
if the patient was still alive. These follow-up data pro-
vided us with detailed survival rates up to 18 years and
were used in this simulation, and if a patient survived
more than 15 years, we assumed that she was in a
remission state and would not die of cervical cancer.
Quality of life
Utilities are a measure of the quality of life rated on a
scale from 0 to 1, where 0 represents death and 1 repre-
sents ideal health. Undiagnosed HPV infection and cer-
vical lesions were considered to be asymptomatic with
no decrease in utility. Diagnosed low- and high-grade
SIL were assigned a lower utility (namely, 0.97) for a
1-year duration [40]. Oncogenic HPV infection can
remarkably affect the quality of life for a woman with
cervical cancer. For invasive cervical carcinoma, a
woman’s utility was assumed to reduce down to 0.70
Figure 1 The Markov decision model. The square on the left represents the prophylactic vaccination decision. Each woman’s health is tracked
by a Markov model after entering the Markov tree (denoted by circles containing an alphabet ‘M’). In each cycle, women are at risk of
developing oncogenic human papillomavirus (HPV) infection, SIL (squamous intraepithelial lesions), cervical cancer or mortality. The Markov tree
branches with ends of rectangles represent the above clinical events that can occur during each 1-year period as a 12-year-old girl is followed
until death.
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Parameters Base case
value
Range for sensitivity
analysis
Data source
Vaccine variables
Vaccine efficacy, % 75 50-100 [10,12,46-48]
Vaccine coverage, % 100 30-100 Assumed
Age for starting vaccination, year 12 12-36 [49]
Immunity duration, year lifetime 10-lifetime [46,47]
Booster shot compliance, % 70 30-100 Assumed
Screening variables
Age for starting cervical screening, year 30 [1,39]
Screening interval, year 1 1-5 [1,39]
Screening compliance, % 15-30 0-70 [1,39]
Pap test sensitivity for SIL 0.60 0.40-0.80 [31,32]
Pap test specificity for SIL 0.97 0.95-0.98 [31,32]
Costs, US$
Vaccine cost (3 doses) 364 273-455 Assumed
Booster shot cost 121 91-152 Assumed
Cost of Pap test 16 12-20 [41]
Cost for a false-positive SIL 66 50-83 [41]
Cost of treatment for cervical cancer 10 000 7 500-12 500 [41]
Cost of treatment for high-grade SIL 245 183-306 [41]
Utilities
Normal population 1 Assumed
Diagnosed SIL for 1-year 0.97 0.80-1 [13,40]
Cervical cancer 0.70 0.25-1 Assumed
Cervical cancer, follow-up 0.95 0.90-1 Assumed
Transition probabilities
Incidence of high-risk HPV infection 0-0.09 0.5-2 × base case [6-9]
HPV infection resolving 0.03-0.46 0.67-1.5 × base case [33-38]
Developing low-grade SIL from high-risk HPV infection 0.065 0.05-0.08 [50-59]
Low-grade SIL regressing 0.027-0.142 0.67-1.5 × base case [13,54-58,60]
Low-grade SIL regressing to previous HPV infection state, given
regression occurs
0.10 0-0.20 [13,54]
Developing high-grade SIL from low-grade SIL 0.005-0.400 0.67-1.5 × base case [50-58]
High-grade SIL regressing 0.037-0.058 0.67-1.5 × base case [13,54-58,60]
High-grade SIL regressing to well state, given regression occurs 0.45 0.40-0.50 [13,54]
High-grade SIL regressing to previous HPV infection state, given
regression occurs
0.05 0-0.10 [13,54]
High-grade SIL regressing to low-grade SIL, given regression
occurs
0.50 0.40-0.60 [13,54]
Developing cervical cancer from high-grade SIL 0.038 0.03-0.06 [50-58]
Annual probability of developing symptoms with undiagnosed
cervical cancer
0-1 [13,54,61,62]
Cervical cancer mortality 0.0024-0.3334 0.67-1.5 × base case Estimated by the National Cancer
Registry of Taiwan
Treatment variables
Treatment efficacy, given high-grade SIL, % 95 90-100 [13,63,64]
HPV infection persists, given effective treatment of high-grade
SIL, %
10 0-25 [13]
Other variables
Discount rate, % 3 0-5 [43]
Cycle length, year 1 Assumed
*HPV denotes human papillomavirus; SIL, squamous intraepithelial lesion. All probabilities are annual unless otherwise noted.
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its effects on her quality of life. Follow-up of cervical
cancer was assigned a moderate utility (0.95) once can-
cer went into remission. The chosen values responded
to our expert criteria.
Costs
Only direct medical costs are considered in this study,
which include the costs associated with the health care
items reimbursed by the National Health Insurance
(NHI) and the out-of-pocket payments such as outpati-
ent registration fees, some drug charges or medical
equipment expenses not covered by the NHI. Pap test-
ing costs were US$16 per test. The cost of treatment for
SIL or cervical cancer was based on cost of initial colpo-
scopy and biopsy, therapy, and subsequent follow-up.
These costs were estimated by published literature of
Tang et al. (2009) [41], expert opinions and official tariff
lists of the NHI. The vaccination cost for three doses
was assumed to be US$364, which include the cost of
the HPV vaccine itself, personnel, and administration.
All costs were reported in 2009 US dollars with the
exchange rate of 33 New Taiwan dollars to US$1.
Vaccine characteristics
We initially assumed the vaccine coverage rate to be
100% in the base case situation, i.e., all women received
the required three doses within 1 year. Moreover, for our
base case analysis, the vaccine was assumed to confer life-
time immunity against acquiring new infections by HPV-
16 and HPV-18. Because vaccine longevity is uncertain,
the waning of vaccine protection over time becomes an
important factor that could not be avoided. We evaluated
the diverse waning scenarios that required booster shots
with different compliance rates in sensitivity analysis. In
the base case setting, vaccine efficacy against oncogenic
types was estimated at 75%. We examined a wide range
of vaccine efficacy (from 50% to 100%) to allow for
further development of HPV vaccines and to deal with
the possibility of lower coverage in Taiwan, where the
prevalence of HPV-16 and HPV-18 infection in cervical
cancer could be lower than 70% [9,42].
Outcome measures
We expressed our results in terms of the number of cer-
vical cancer cases prevented and deaths avoided, as well
as the life-years and quality-adjusted life-years (QALY)
gained over a lifetime. The incremental cost-effective-
ness ratio (ICER) was calculated as the accumulated
total cost difference divided by the QALY gained per
woman by adding vaccination to existing screening. The
economic analysis adopted a 3% annual discount rate
for future costs and outcomes, which converts values
that will occur in the future to their present value.
Sensitivity analysis
Sensitivity analyses were performed to account for
important model assumptions and uncertainties
including the vaccine characteristics, adherence to cervi-
cal screening, costs or health utilities for various condi-
tions, parameters related to the natural history of
disease, discount rate, etc; we also examined the impact
of starting vaccination at different ages on the cost-
effectiveness ratio for HPV vaccine in sensitivity analy-
sis. The ranges for costs were varied from minus 25% to
plus 25% of the base case estimate. For clinical variables,
our ranges for sensitivity analysis represented our judg-
ment of the uncertainties and/or variations likely to be
encountered in clinical practice, based on both the lit-
erature and the opinions of experts (Table 1).
Results
Model validation
Due to the main interests of this study and the certainty
of data sources, cervical cancer incidence and mortality
were chosen as primary endpoints for the model calibra-
tion process of matching the outputs in the current
practice arm without vaccination of the model to
observed cancer statistics. The model predicted the inci-
dence rate for cervical cancer would be 21.1 per 100,000
females 12 or older, given the assumption that women
would receive cervical screening with compliance rates
of the current practice. Predicted cervical cancer inci-
dence showed good correspondence with observed data
from the National Cancer Registry of Taiwan between
2001 and 2005 that the overall incidence of cervical can-
cer cases was 22.7 per 100,000 females aged over 10
years (Figure 2). Moreover, the predicted HPV preva-
lence and cervical cancer mortality were also fit reason-
ably well to the observed epidemiological data, with the
exception of a slightly lower mortality for ages over 65.
The predicted cervical cancer mortality would be 7.2
per 100,000 females 12 or older, while the observed
overall cervical cancer mortality was 7.8 per 100,000
people for women aged over 10 years.
Base case analysis
In our base case analysis, the administration of HPV
vaccine could reduce 73.3% of the total incident cervical
cancer cases from 1,773 to 473 per 100,000 women and
lessen 73.4% of cancer deaths from 710 to 189 per
100,000 women over the lifetime of the cohort of 12-
year-old girls. On average, their life expectancy would
be improved by 4.9 days or 0.024 QALY. Adding an
HPV vaccine was more expensive than current practice,
with an overall increase in estimated lifetime discounted
cost of US$324. The incremental cost-effectiveness ratio
based on this model was US$13,674 per QALY gained
(Table 2).
Sensitivity analysis
On the basis of our sensitivity analyses of various para-
meters, the model suggested that the ICER of adding
vaccination strategy, as compared to the current
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vaccine immunity longevity or booster frequency, inci-
dence of high-risk HPV infection, compliance with Pap
testing, vaccine efficacy and in quality of life for cervical
cancer. Changes in these parameters could result in
wider variations of the ICER, as depicted in Figure 3.
The incremental cost of vaccination would be usually
less than US$30,000/QALY relative to the current prac-
tice when the efficacy was greater than 37%. If
vaccination required a one-shot booster every 10 years,
then the ICER would increase to US$37,150/QALY
which multiplied by 2.7 the base case outcome under
lifelong immunization (Figure 4). The ICER would
remain below US$30,000/QALY if the interval of boos-
ter shots needed to maintain the immunity was over 13
years.
Vaccination cost-effectiveness, however, would be US
$37,480/QALY at a discounted rate of 5% since higher
Figure 2 Calibration results of age-specific incidence and mortality of cervical cancer. The circles and bars represent the observed cancer
incidence and mortality from the National Cancer Registry of Taiwan, respectively. The squares and hollow bars represent the predicted cancer
incidence and mortality by the Markov model in which the current practice of cervical screening was applied from 30 years of age without
vaccination.
Table 2 Health and economic outcomes of HPV vaccination, discounted
Outcome No vaccination HPV vaccination
Cost, US$ 129 453
Incremental cost, US$ 324
Life expectancy, years 28.830 28.844
Incremental life expectancy, days 4.9
Quality-adjusted life expectancy, years 28.816 28.840
Incremental quality-adjusted life expectancy, days 8.7
Incremental cost-effectiveness ratio
US$/life year 23 939
US$/quality-adjusted life year 13 674
HPV denotes human papillomavirus
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vaccination costs.
If every woman in Taiwan obtained a Pap test every 3
years from the age of 30, the ICER of vaccination would
slightly increase to US$17,199/QALY.
Discussion
Our analysis demonstrated that under most assump-
tions, the prophylactic vaccination against HPV-16 and
HPV-18 had an ICER between US$7,000 and US$27,000
per QALY gained in the vaccinated adolescent girls in
Taiwan. The ICER would remain below US$30,000 per
QALY unless the vaccine efficacy declined to less than
38% or if the immunity waned and required booster
shots every 10 years (Figure 4). If the vaccination cost
could be reduced to below US$277, then the HPV vacci-
nation would cost less than US$10,000 per QALY
gained, indicating a potential for further enhancement
of cost-effectiveness. Although there has been no
domestic consensus on the threshold of the cost-effec-
tiveness ratio for the National Health Insurance system
to decide whether to reimburse a new medical interven-
tion, the results of our analysis suggest that prophylactic
vaccination against oncogenic HPV administered in pre-
adolescent girls in Taiwan would be usually cost-
effective based on the World Health Organization pro-
posed criteria of 1-3 times the gross domestic product
(GDP) per capita being cost-effective or less than GDP
per capita being very cost-effective [43] since the GDP
per capita of Taiwan was approximately US$17,082 in
2008.
In addition to the discount rate, the duration of the
vaccine immunity accounted for the most influential
source of variations in the ICER of incorporating HPV
vaccination within our investigation (Figure 3), which is
consistent with other studies [27]. Compared to the pre-
vious studies mostly performed in Western countries
[16,22-26], the HPV vaccination strategy in our study
appeared to be attractive in terms of a lower ICER.
However, this figure of cost-effectiveness in Taiwan
could be largely owing to the high prevalence of HPV
infection [6-9] and lower compliance rate with cervical
cytological screening [1] that resulted in higher back-
ground incidence of cervical cancer, since we employed
similar assumptions of time horizon, discount rate, vac-
cine efficacy and lifelong vaccine protection as most of
those studies. For example, as the projected incidence of
cervical cancer under the current screening practice in a
study from the Netherlands [26] was lower than that in
our study by 3.5 times and the vaccination costs were
Figure 3 One-way sensitivity analyses on the incremental cost-effectiveness ratio (ICER). The range of input parameter for the sensitivity
analysis is indicated in the parentheses on the left of the vertical axis. The vertical line represents the ICER under base case assumptions. The
numbers in brackets alongside the bar represent the ratio between the maximum value (right) and the minimum one (left) in sensitivity analysis
respectively over the base case ICER.
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was much higher than the figure in our study (approxi-
mately 5.8 times).
Methodological differences may also account for varia-
tions in the results of different cost-effectiveness evalua-
tions [27,44]. Although dynamic transmission model has
been developed and applied [17,18,22,23,25,28], it gener-
ally requires investigators to make more assumptions on
putting into parameter values related to viral transmis-
sion. As the sexual behavior in adolescents and young
people in Taiwan may be different from that in western
countries and the relevant data were insufficient, we
took an alternative approach to adapt a simpler Markov
model as previous studies [13,14,24], but more delicately
adjusted the model with existing clinical and epidemio-
logical data of cervical cancer in Taiwan. Our approach
d i dn o tc o n s i d e rt h eh e r di m m u n i t ya n dt h ep r o t e c t i o n
by HPV vaccination for genital warts or other HPV
related cancers. Thus, we would underestimate the over-
all effectiveness of the vaccination program, which
would generally make the cost-effectiveness of the HPV
vaccine even more favorable if herd immunity or protec-
tion for other diseases existed [21,45].
The relatively high risk level of invasive cervical cancer
in Taiwan implies the urgency to improve the compli-
ance rate of cervical screening to the early detection of
SIL and cervical cancer, even though the ICER of pro-
phylactic vaccination would rise accordingly because the
marginal effectiveness of vaccination would be dimin-
ished as improvement in cytological screening would
decrease the baseline incidence of invasive cervical can-
cer without adding HPV vaccination. Moreover, during
the model calibration process, we discovered an upward
trend of cervical cancer incidence by age that reflected
inadequate compliance with cervical screening among
older women, particularly those older than 60 years
(Figure 2). Had the cervical screening compliance for
older women improved to be comparable with those of
younger women, the cumulative incident cases with cer-
vical cancer would have decreased in both cohorts with
or without vaccination, while the ICER of HPV vaccine
would go up slightly to US$14,120 per QALY gained.
Figure 4 Sensitivity analysis of the incremental cost-effectiveness of vaccination compared to the current practice, with respect to the
change in human papillomavirus (HPV) vaccine efficacy and immunity longevity. The squares represent a vaccine providing lifetime
immunity to HPV-16 and HPV-18 (base case assumption). The triangles represent a vaccine that requires booster shots every 20 years to remain
effective. The circles represent a vaccine that needs booster shots every 10 years to maintain effectiveness.
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text of HPV vaccination. As in any economic assessment
of a preventive measure with later-onset effects, the
initial intervention costs and the choice of discount rate
have a significant influence on the cost-effectiveness
results. In general, higher discount rates would make
the prophylactic vaccination strategy seem less attrac-
tive, given that the costs of the intervention are paid
immediately while the benefits come back many years
later. Indeed, we found the undiscounted ICER of vacci-
nation on 12-year-old girls was US$1,820 per QALY
gained, whereas the ICER significantly increased to US
$37,480 per discounted QALY gained at a discounted
rate of 5%.
There are limitations in this study. First, herd immunity
effects were not taken into account in our model as dis-
cussed above. Second, women adherent to previous cervi-
cal screening tests tended to have better compliance with
subsequent tests [1]. The preventive effects of screening
could therefore be overestimated particularly for those at
older ages, which in turn would underestimate the effec-
tiveness of vaccination. Thus, the current ICER of HPV
vaccine would be a conservative estimation, as the ICER
should further decline if the actual compliance rates of
cervical screening were adjusted with a lower coverage.
Nonetheless, the conservative assessment for the ICER of
HPV vaccine in our study, together with the results of
other relevant research [28,29], would increase the cred-
ibility of the cost-effectiveness for a prophylactic HPV
vaccination program in Taiwan.
Conclusions
Our analysis suggested that vaccination of adolescent
girls with an HPV vaccine seems to be cost-effective in
Taiwan where the HPV infection rate and the incidence
as well as the mortality of cervical cancer are relatively
higher than those in other developed countries.
Although there are still some uncertainties regarding
the HPV vaccine and cervical cytological screening, our
estimation of the cost-effectiveness for a prophylactic
vaccine against high-risk HPV, however, appears to be
r o b u s t .W eh a v ed e m o n s t r a t e dt h a tt h eI C E Rw o u l d
usually fall below US$30,000 per QALY gained under
most assumptions, which also covers a wide range of
vaccination strategies and vaccine characteristics. Even
in the case of favorable cost-effectiveness ratio of pro-
phylactic vaccination against oncogenic HPV, there is
still room for improvement of the compliance with Pap
screening tests in Taiwan, especially for older women,
because vaccination should not yet be regarded as the
substitute for cytological screening. It calls attention to
the importance of continuing research that investigates
primary and secondary preventive measures against cer-
vical cancer.
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